Neurizon Therapeutics in the NEWS

Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), and U.S (ECQO.F), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the U.S. FDA has lifted the clinical hold on its lead investigational drug, NUZ-001.

This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 . . .